These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15896099)

  • 1. Economic considerations in the prescribing of third-generation antidepressants.
    Montgomery S; Doyle JJ; Stern L; McBurney CR
    Pharmacoeconomics; 2005; 23(5):477-91. PubMed ID: 15896099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses.
    Machado M; Iskedjian M; Ruiz IA; Einarson TR
    Pharmacoeconomics; 2007; 25(11):979-90. PubMed ID: 17960955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine. A pharmacoeconomic evaluation of its use in depression.
    Wilde MI; Whittington R
    Pharmacoeconomics; 1995 Jul; 8(1):62-81. PubMed ID: 10155603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit analysis of newer versus older antidepressants--pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants.
    Laux G
    Pharmacopsychiatry; 2001 Jan; 34(1):1-5. PubMed ID: 11229615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients.
    Priest RG
    Clin Ther; 1996; 18(2):347-58; discussion 302. PubMed ID: 8733994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic comparisons of the pharmacotherapy of depression: an overview.
    Crott R; Gilis P
    Acta Psychiatr Scand; 1998 Apr; 97(4):241-52. PubMed ID: 9570483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and economic impact of antidepressant medications: a review.
    Mitchell J; Greenberg J; Finch K; Kovach J; Kipp L; Shainline M; Jordan N; Anderson C
    Am J Manag Care; 1997 Feb; 3(2):323-30; quiz 331. PubMed ID: 10169266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical review of selected pharmacoeconomic analyses of antidepressant therapy.
    Conner TM; Crismon ML; Still DJ
    Ann Pharmacother; 1999 Mar; 33(3):364-72. PubMed ID: 10200863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
    Lenox-Smith A; Conway P; Knight C
    Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic studies of antidepressants: focus on venlafaxine.
    Woods SW
    Depress Anxiety; 2000; 12 Suppl 1():102-9. PubMed ID: 11098423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.
    Freeman H; Arikian S; Lenox-Smith A
    Pharmacoeconomics; 2000 Aug; 18(2):143-8. PubMed ID: 11067648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant treatment for depression: total charges and therapy duration*.
    Dobrez DG; Melfi CA; Croghan TW; Kniesner TJ; Obenchain RL
    J Ment Health Policy Econ; 2000 Dec; 3(4):187-197. PubMed ID: 11967455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France.
    Nuijten M; Hadjadjeba L; Evans C; van den Berg J
    Pharmacoeconomics; 1998 Oct; 14(4):433-45. PubMed ID: 10344910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choosing an antidepressant: effectiveness based pharmacoeconomics.
    Stewart A
    J Affect Disord; 1998 Mar; 48(2-3):125-33. PubMed ID: 9543201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost analysis of paroxetine versus imipramine in major depression.
    Bentkover JD; Feighner JP
    Pharmacoeconomics; 1995 Sep; 8(3):223-32. PubMed ID: 10155618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.
    Henry JA; Rivas CA
    Pharmacoeconomics; 1997 May; 11(5):419-43. PubMed ID: 10168031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics.
    Goldstein BJ; Goodnick PJ
    J Psychopharmacol; 1998; 12(3 Suppl B):S55-87. PubMed ID: 9808079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost savings with nefazodone in treating depression.
    Hales RE; Hilty DM; Brunson GH
    J Clin Psychiatry; 2002; 63 Suppl 1():48-51. PubMed ID: 11890565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.